0 (0%)		12-05 09:28
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	29.14	1-year :	34.03
Resists	First :	24.95	Second :	29.14
Pivot price	23.7
Supports	First :	22.08	Second :	20.31
MAs	MA(5) :	23.9	MA(20) :	23.48
	MA(100) :	23.97	MA(250) :	0
MACD	MACD :	0.2	Signal :	0.1
%K %D	K(14,3) :	67.2	D(3) :	66.7
RSI	RSI(14): 55.9
52-week	High :	27.63	Low :	18.17

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ PCRX ] has closed below upper band by 34.9%. Bollinger Bands are 40% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	24.35 - 24.47	24.47 - 24.57
Low:	23.63 - 23.77	23.77 - 23.87
Close:	23.77 - 23.99	23.99 - 24.16

Fri, 05 Dec 2025
How Investors Are Reacting To Pacira BioSciences (PCRX) Spine Pain Trial Win And New FDA Clearance - simplywall.st

Wed, 03 Dec 2025
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain - Yahoo Finance

Wed, 03 Dec 2025
Pacira BioSciences (PCRX) Awards Inducement Grants to New Employ - GuruFocus

Wed, 03 Dec 2025
Pacira BioSciences (Nasdaq: PCRX) issues 2,200 inducement RSUs to two new employees - Stock Titan

Wed, 03 Dec 2025
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Pfizer (PFE) and Janux Therapeutics Inc (JANX) - The Globe and Mail

Tue, 02 Dec 2025
Does Pacira’s ioveradeg Pilot Data and Smart Tip Clearance Change The Bull Case For Pacira (PCRX)? - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	43 (M)
Shares Float	43 (M)
Held by Insiders	1.8 (%)
Held by Institutions	113.4 (%)
Shares Short	7,280 (K)
Shares Short P.Month	5,950 (K)

EPS	0.46
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	16.92
Profit Margin	2.9 %
Operating Margin	7.3 %
Return on Assets (ttm)	2.8 %
Return on Equity (ttm)	2.9 %
Qtrly Rev. Growth	6.5 %
Gross Profit (p.s.)	10.94
Sales Per Share	16.66
EBITDA (p.s.)	3.5
Qtrly Earnings Growth	0 %
Operating Cash Flow	141 (M)
Levered Free Cash Flow	78 (M)

PE Ratio	51.02
PEG Ratio	0
Price to Book value	1.41
Price to Sales	1.43
Price to Cash Flow	7.29

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.